Table 3.
Univariate and multivariate analysis for overall survival
| Category | Univariate | Multivariate | ||
|---|---|---|---|---|
| HR (95% CI) | p valuea | HR (95% CI) | p valuea | |
| KRAS exon 2 mutation: G12C vs. non‐G12C | 1.50 (1.08–2.08) | .015 | 1.42 (1.01–2.00) | .044 |
| Age: ≥65 vs. <65 years | 1.03 (0.87–1.22) | .725 | ||
| Gender: Male vs. female | 0.90 (0.76–1.07) | .219 | ||
| ECOG PS: 1 or 2 vs. 0 | 1.78 (1.46–2.17) | <.001 | 1.25 (1.00–1.57) | .049 |
| Primary tumor site: left vs. right | 0.82 (0.68–0.98) | .028 | 0.99 (0.82–1.21) | .976 |
| Surgery on primary tumor: Yes vs. no | 0.58 (0.48–0.69) | <.001 | 0.75 (0.60–0.93) | .010 |
| Time of first metastasis: Synchronous vs. metachronous | 1.47 (1.23–1.77) | <.001 | 0.95 (0.76–1.19) | .647 |
| Histology: por/muc vs. well/mod | 1.44 (1.07–1.94) | .016 | 1.44 (1.06–1.95) | .021 |
| Serum LDH, IU/L: ≥210 (median) vs. <210 | 1.93 (1.62–2.30) | <.001 | 1.59 (1.31–1.92) | <.001 |
| GPS: 1 or 2 vs. 0 | 2.31 (1.83–2.90) | <.001 | 1.64 (1.27–2.12) | <.001 |
| Number of metastatic organ site: ≥2 vs. 1 | 1.63 (1.37–1.94) | <.001 | 1.45 (1.21–1.74) | <.001 |
| First‐line backbone regimen: Doubletb or tripletc vs. monod | 0.60 (0.41–0.90) | .012 | 0.76 (0.50–1.17) | .219 |
| First‐line bevacizumab: Yes vs. no | 0.69 (0.55–0.86) | <.001 | 0.84 (0.66–1.08) | .174 |
a
Values of p were calculated using the Cox proportional hazard model.
b
Doublet indicates oxaliplatin‐based regimens (FOLFOX, CAPOX, and SOX) or irinotecan‐based regimens (FOLFIRI, IRIS [SIRB], CAPIRI).
c
Triplet indicates FOLFOXIRI.
d
Mono indicates 5‐fluorouracil (5‐FU)/leucovorin (LV), capecitabine, tegafur‐uracil (UFT)/LV, or S‐1 monotherapy.
Abbreviations: CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; GPS, Glasgow prognostic score; HR, hazard ratio; KRAS, Kirsten rat sarcoma; LDH, lactate dehydrogenase; mod, moderately differentiated; muc, mucinous adenocarcinoma; poor, poorly differentiated; well, well differentiated.